It's like Google's AI for cancer drug discovery.

Think of it as a biotech company like Amgen, but with AI as its core engine for finding new treatments.

It's like DeepMind focused entirely on accelerating oncology drug development.

• LP-100: An advanced drug candidate in phase II clinical trials for metastatic, castration-resistant, and prostate cancer.
• LP-300: A drug candidate developed as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma.
• LP-184: A preclinical development drug candidate, an alkylating agent designed to damage DNA in cancer cells with specific biomarkers or DNA repair pathway mutations.
• ADC program: An antibody drug conjugate therapeutic approach currently in development for cancer treatment.
• RADR platform: An artificial intelligence platform that utilizes big data analytics and machine learning to combine molecular data for drug development.

Based on the provided company description, Lantern Pharma Inc. (LTRN) is a clinical-stage biotechnology company focused on the research and development of its own drug candidates. Its primary activities involve advancing drugs like LP-100, LP-300, and LP-184 through clinical and preclinical trials, and utilizing its AI platform RADR internally for drug discovery.

At its current stage of development, Lantern Pharma does not have major customers in the traditional sense, as it is not yet commercializing or selling its drug products or its AI platform to other companies or individuals. Its focus remains on the scientific and clinical progression of its drug pipeline.

Panna Sharma, Chief Executive Officer, President and Director

Panna Sharma joined Lantern Pharma in 2018. Prior to his role at Lantern Pharma, he served as the President and Chief Executive Officer of Cancer Genetics, Inc. (Nasdaq: CGIX) from 2010 to 2018. During his tenure at Cancer Genetics, Inc., he successfully raised over $100 million in public and private markets, expanded the company from 25 to over 250 employees globally, took the company public in 2013, and oversaw the acquisition of four companies. Mr. Sharma also founded TSG Partners, a specialty advisory group focused on corporate strategy and finance in the life sciences, biotechnology, and environmental sciences sectors. He has played a role in four IPOs and been involved with five public companies as CEO, CSO, or board member and advisor. Additionally, he founded and chairs Starlight Therapeutics, a clinical-stage biotech venture.

David R. Margrave, Chief Financial Officer and Secretary

David R. Margrave has served as Lantern Pharma's Chief Financial Officer since November 2019 and Secretary since June 2018. Before joining Lantern Pharma, he worked as a life science consultant from January 2016 to November 2019. From 1995 to 2015, Mr. Margrave was an executive officer at BioNumerik Pharmaceuticals, Inc., where he held various positions including President, Chief Administrative Officer, and General Counsel. Notably, Lantern Pharma acquired the IP for LP-300 from BioNumerik in 2018, a company in which Mr. Margrave previously held a minority interest. He also served as Senior Legal Advisor to MedCare Investment Corporation, a private investment firm, from April 2015 to December 2016. Prior to BioNumerik, he was a partner at the national law firm Andrews & Kurth LLP.

Kishor G. Bhatia, PhD, Chief Scientific Officer

Dr. Kishor G. Bhatia has been Lantern Pharma's Chief Scientific Officer since December 2019, after serving as a scientific consultant since January 2019. His experience includes working as a scientific consultant for Reprocell since December 2016 and for Cancer Genetics, Inc. from December 2016 to November 2019. Since 2006, Dr. Bhatia has also been an Adjunct Investigator with the National Cancer Institute-Division of Cancer Epidemiology and Genetics.

Marc Chamberlain, MD, Starlight Therapeutics, Chief Medical Officer

Dr. Marc Chamberlain serves as the Chief Medical Officer for Starlight Therapeutics, a Lantern Pharma subsidiary. He is a prominent medical oncologist with extensive experience in therapeutic development, clinical practice, and academic research, specializing in adult and pediatric neurology and neuro-oncology. Dr. Chamberlain has co-directed neuro-oncology programs at several NCI-designated cancer centers, including Moores Cancer Center at UC San Diego, Norris Cancer Center at USC, Moffit Cancer Center at the University of South Florida, and Fred Hutchinson Cancer Center at the University of Washington.

Reggie Ewesuedo, MD, MBA, Vice President, Clinical Development

Dr. Reggie Ewesuedo holds the position of Vice President, Clinical Development at Lantern Pharma.

1. Clinical Trial Failure and Regulatory Hurdles: The most significant risk for Lantern Pharma stems from the inherent uncertainty and high attrition rate associated with pharmaceutical research and development. The success of its primary drug candidates, such as LP-100 in Phase II for metastatic, castration-resistant, and prostate cancer, LP-300 as a combination therapy for non-small cell lung cancer adenocarcinoma, and the preclinical LP-184, is critical to the company's future. Clinical trials are lengthy, costly, and typically have low success rates across all stages, with many compounds failing to progress beyond initial phases or achieve regulatory approval. The failure of any of these candidates in trials or an inability to obtain necessary regulatory approvals (e.g., from the FDA) would severely impact the company's ability to commercialize products and generate revenue.
2. Funding and Capital Raising Challenges: Developing pharmaceutical drugs is an extremely capital-intensive endeavor, requiring substantial investment in research, development, and clinical trials. As a clinical-stage company, Lantern Pharma currently reports no revenue. The company's financial health analysis indicates a "fairly risky" cash burn and a relatively short cash runway, suggesting a continuous need to raise additional capital to fund its ongoing operations and advancement of its drug pipeline. The inability to secure sufficient funding through equity financing could lead to significant shareholder dilution or, in a worst-case scenario, halt drug development programs entirely.
3. Intense Competition and Reliance on AI Platform: The oncology drug market is highly competitive, with numerous pharmaceutical and biotechnology companies vying to develop new treatments. Even if Lantern Pharma's drug candidates prove safe and effective, they must demonstrate superior efficacy, safety, or other advantages to gain market share against existing and emerging therapies. Furthermore, a core component of Lantern Pharma's strategy is its proprietary artificial intelligence (AI) platform, RADR, which is used to streamline drug discovery and development. There is a risk that this AI platform may not deliver the expected efficiencies or competitive advantages, or that competitors could develop superior AI tools, thereby diminishing Lantern Pharma's strategic differentiation and ability to accelerate drug development.

Lantern Pharma (NASDAQ: LTRN) operates in several significant addressable markets with its main product candidates and programs:

• LP-100 (Metastatic Castration-Resistant Prostate Cancer - mCRPC): The global market for metastatic castration-resistant prostate cancer (mCRPC) was estimated at approximately USD 6.8 billion in 2023, with projections to reach USD 12.84 billion by 2035. The U.S. market alone for mCRPC was approximately USD 4.4 billion in 2023. Another estimate for the global mCRPC therapeutics market size valued it at USD 21.04 billion in 2025, with a projection to reach USD 91.85 billion by 2034. North America held a significant share of 87.63% of this market in 2025.
• LP-300 (Non-Small Cell Lung Cancer Adenocarcinoma in non or never-smokers): The adenocarcinoma segment is anticipated to be the largest portion of the non-small cell lung cancer (NSCLC) market, projected to account for 50% or USD 31,944 million globally in 2029. The global non-small cell lung cancer market was estimated at USD 20.2 billion in 2024 and is expected to grow to USD 53.9 billion by 2034. North America is the largest regional market within NSCLC. The non-small cell lung cancer market, including adenocarcinoma, was valued at USD 30,349.97 million globally in 2025 and is expected to reach USD 65,434.63 million by 2032.
• LP-184 (Cancers with DNA Damage Repair Deficiencies/Biomarker Overexpression): Lantern Pharma estimates that LP-184 targets an addressable market exceeding USD 10 billion in annual drug sales within the U.S., specifically for the estimated 20-25% of solid tumor patients with DNA Damage Repair (DDR) deficiencies, representing over 400,000 cases annually. For Triple-Negative Breast Cancer (TNBC), one of the indications for LP-184, the annual market opportunity is estimated to exceed USD 4 billion. The global TNBC market is estimated at USD 3-5 billion annually. For advanced non-small cell lung cancer (NSCLC) patients with KEAP1 and/or STK11 mutations and low PD-L1 expression, where LP-184 is being evaluated, the annual market opportunity is estimated to be in excess of USD 2 billion (likely U.S.).
• ADC Program (Antibody Drug Conjugates): The global cancer antibody drug conjugates (ADC) market was valued at USD 9.17 billion in 2025 and is projected to reach USD 15.77 billion by 2030. Other estimates place the global ADC market size at USD 10.77 billion in 2024, projected to grow to USD 34.32 billion by 2032. Another report states the global market size for ADCs was USD 12.69 billion in 2025 and is predicted to increase to approximately USD 34.80 billion by 2035. North America was the largest region in the cancer antibody drug conjugates market in 2025, accounting for 50% of the global market share.

Lantern Pharma Inc. (LTRN) is poised for future revenue growth over the next 2-3 years, driven by the advancement of its clinical-stage drug candidates and the commercialization of its artificial intelligence (AI) platform. The company's strategy leverages its proprietary RADR® AI and machine learning platform to streamline oncology drug development.

Here are 3-5 expected drivers of future revenue growth for Lantern Pharma:

1. Advancement and Potential Commercialization of LP-184: LP-184 is a key drug candidate with significant market potential. Having completed Phase 1a clinical trials and established the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), LP-184 is set to advance into planned Phase 1b/2 trials in multiple indications, including recurrent triple-negative breast cancer (TNBC), recurrent bladder cancer, NSCLC with STK11/KEAP1 co-mutations, and recurrent glioblastoma (GBM). These indications represent an estimated annual market potential of $10-12 billion. The planned initiation of Phase 1b/2 trials in Q1 2026 and an investigator-led bladder cancer trial in H1 2026 highlight the near-term progress expected to drive future revenue.
2. Advancement and Potential Commercialization of LP-300: LP-300 is being developed as a combination therapy for non or never-smokers with non-small cell lung cancer (NSCLC) adenocarcinoma. The HARMONIC™ Phase 2 trial has shown promising results, including a remarkable complete response in a patient with advanced NSCLC who had previously failed other therapies. Additional data and clinical findings from this trial were anticipated in September 2025, with further patient follow-up and clinical data expected in December 2025. Regulatory allowance to begin Phase 2 enrollment in Japan and Taiwan (where never-smokers with NSCLC represent a significant population), with enrollment completed in Japan by July 2025, positions LP-300 for potential partnership announcements in 2026. The global market potential for LP-300 is estimated to exceed $2.6 billion annually.
3. Commercialization of the RADR® AI Platform and Strategic Partnerships: Lantern Pharma's proprietary RADR® AI platform is a significant asset with commercialization potential. The company has launched modules such as PredictBBB.ai™, an AI module for predicting blood-brain barrier permeability, addressing a critical challenge in CNS drug development with a projected market growth from $1.4 billion in 2023 to $9.85 billion by 2032. The establishment of an AI Center of Excellence in India is aimed at industrializing the RADR® platform and accelerating global development opportunities with biopharma partners, indicating a strategic move to scale its AI capabilities across oncology and into new disease categories. Expected collaborations, licensing agreements, and the commercial availability of select RADR® AI modules for the scientific and research community are anticipated to generate revenue.
4. Advancement of LP-284 and Starlight Therapeutics (STAR-001): LP-284, another synthetic lethal drug candidate, has demonstrated a complete metabolic response in a patient with aggressive diffuse large B-cell lymphoma (DLBCL). The combined annual global sales market potential for LP-184 and LP-284 across multiple cancer indications is estimated to be over $12 billion. Starlight Therapeutics, a wholly-owned subsidiary, focuses on CNS and brain cancers with its drug candidate STAR-001. Planned pediatric CNS cancer trial initiation through Starlight Therapeutics is expected in Q1 2026, with the market potential for STAR-001 estimated at $4.5 billion to $5+ billion annually. These developments signify a growing pipeline with diverse opportunities for future revenue.

Share Repurchases

• Lantern Pharma initiated a share repurchase program in November 2021.
• As of March 21, 2022, the company had repurchased 475,157 shares of common stock for approximately $3.4 million.
• The program was extended through July 31, 2022, with authorization to purchase up to an additional $3.6 million of common stock.

Share Issuance

• In January 2021, Lantern Pharma completed a secondary public offering (SPO) that raised $60 million by issuing 4,285,715 shares at $14 per share.
• The company utilized at-the-market (ATM) sales, a form of share issuance, as disclosed in its Q3 2025 10-Q report.
• As of November 5, 2025, the number of outstanding shares was 11,184,423, reflecting a 3.6% increase from the prior quarter.

Inbound Investments

• A Bios-affiliated investment group held 960,026 common shares, representing 8.58% of the outstanding stock as of November 5, 2025, indicating a significant institutional investment.
• Lantern Pharma has 45 institutional owners and shareholders collectively holding 2,286,989 shares.

Capital Expenditures

• Lantern Pharma Inc. reported capital expenditures of $555 in Q3 2025.
• The company anticipates its cash, cash equivalents, and marketable securities, totaling approximately $12.4 million as of September 30, 2025, will cover anticipated operating expenses and capital expenditure requirements into approximately Q3 2026.
• Lantern Pharma announced the establishment of an A.I. Center of Excellence in India, aimed at industrializing its RADR platform and accelerating global development opportunities with BioPharma companies.